People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. | — | Pharmaceuticals | Series C | $77.5M | $269.0M | 2025 |
Mark B. Prygocki at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark B. Prygocki on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Manning | 1 | 6 |
| Paul B. Manning | 1 | 6 |
| Sean Stalfort | 1 | 5 |
| Noah Rosenberg | 1 | 3 |
| Diem B. Nguyen | 1 | 2 |
| Matthew Davidson | 1 | 2 |
| Jayson Rieger | 1 | 2 |
| James C. Reebals | 1 | 2 |
| John Kirby | 1 | 2 |
| Anthony C. Cavallo | 1 | 1 |
| Gavin B. Corcoran | 1 | 1 |
| David Zawitz | 1 | 1 |
| Lawrence B. Eichenfield | 1 | 1 |
| Sean B. Stalfort | 1 | 1 |
| Joseph Bonaccorso | 1 | 1 |
| Ted White | 1 | 1 |
| Glenn Oclassen | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.